Cambridge, MA - CluePoints, a leading provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, today announced their collaboration with Oracle Health Sciences, combining CluePoints' award-winning risk-based monitoring (RBM) solution with Oracle’s clinical data capture and management platform, Oracle Health Sciences Inform Cloud Service. The resulting solution can help deliver a complete trial review process that proactively identifies risk in both clinical and operational data throughout a clinical trial. These include operational risks, such as those outlined by industry consortiums, as well as risks seen through the analysis of clinical data that highlight anomalies or inconsistent data patterns at study, region or site levels that otherwise may not have been identified.
This collaboration brings together CluePoints' Central Statistical Monitoring (CSM) solution, which identifies anomalous data and site errors, with clinical and operational data from Oracle Health Sciences to analyze and identify risks, and ultimately optimize both remote and on-site monitoring. By offering sponsors and CROs full evaluation and proactive identification of risks identified through both clinical and operational data, customers are able to respond to signals and anomalies that could impact patient safety and the quality of results, while also driving informed decision-making for future stages of a trial and minimizing subsequent regulatory submission risk.
The combination of CluePoints' solution and Oracle's holistic RBM cloud platform can allow identification of risks based on patient data, site level or region using clinical data from the InForm platform, and, as a result, complementing existing RBM capabilities that identify operational risks for a study. The detection of risks identified through both operational and clinical data provides customers with the ability to fully respond to data issues and make changes to study protocols to effectively address and minimize study risk.
"We are thrilled to be working with Oracle Health Sciences on the integration of our technologies," says FranÒ«ois Torche, CEO, CluePoints. "It is well understood how vital accurate data is to a clinical trial. By bringing together a combined technology solution, customers can now proactively resolve risks and ensure that they have detailed insight into data at all stages of a clinical trial."
CluePoints and Oracle Health Sciences have announced an upcoming webinar, entitled 'De-risking It All - A Systematic and Proven Approach to RBM and Data Quality Oversight", providing the opportunity to learn from industry experts how a unique combination of data analytics and Electronic Data Capture is being harnessed by large, medium and smaller Pharma to de-risk clinical studies and drive Risk-Based Monitoring. To register, please visit this website today.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.